+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

BioCryst Pharmaceuticals Inc (BCRX) - Financial and Strategic SWOT Analysis Review

BioCryst Pharmaceuticals Inc (BCRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioCryst Pharmaceuticals Inc (BioCryst) is a biotechnology company that designs, optimizes and develops small molecule drugs that block critical enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary angioedema. The company’s other pipeline products include, BCX10013 and BCX9250. It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through a process known as structure-guided drug design. BioCryst’s products include peramivir injections, which consist of Rapivab, Alpivab, Rapiacta, Orladeyo and Peramiflu for the treatment of Influenza. BioCryst is headquartered in Durham, North Carolina, the US.

BioCryst Pharmaceuticals Inc Key Recent Developments

  • Mar 31, 2023: BioCryst Appoints Dr. Nancy Hutson as Chair of the Board
  • Feb 21, 2023: BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
  • Jan 24, 2023: BioCryst and Swixx BioPharma partner for commercialisation of Orladeyo
  • Nov 01, 2022: BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • BioCryst Pharmaceuticals Inc - Key Facts
  • BioCryst Pharmaceuticals Inc - Key Employees
  • BioCryst Pharmaceuticals Inc - Key Employee Biographies
  • BioCryst Pharmaceuticals Inc - Major Products and Services
  • BioCryst Pharmaceuticals Inc - History
  • BioCryst Pharmaceuticals Inc - Company Statement
  • BioCryst Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • BioCryst Pharmaceuticals Inc - Business Description
  • R&D Overview
  • BioCryst Pharmaceuticals Inc - Corporate Strategy
  • BioCryst Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • BioCryst Pharmaceuticals Inc - Strengths
  • BioCryst Pharmaceuticals Inc - Weaknesses
  • BioCryst Pharmaceuticals Inc - Opportunities
  • BioCryst Pharmaceuticals Inc - Threats
  • BioCryst Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • BioCryst Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 31, 2023: BioCryst Appoints Dr. Nancy Hutson as Chair of the Board
  • Feb 21, 2023: BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
  • Jan 24, 2023: BioCryst and Swixx BioPharma partner for commercialisation of Orladeyo
  • Nov 01, 2022: BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones
  • Sep 14, 2022: BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer
  • Aug 04, 2022: BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
  • Feb 23, 2022: BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
  • Feb 08, 2022: BioCryst Appoints Machelle Sanders to Board of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • BioCryst Pharmaceuticals Inc, Key Facts
  • BioCryst Pharmaceuticals Inc, Key Employees
  • BioCryst Pharmaceuticals Inc, Key Employee Biographies
  • BioCryst Pharmaceuticals Inc, Major Products and Services
  • BioCryst Pharmaceuticals Inc, History
  • BioCryst Pharmaceuticals Inc, Other Locations
  • BioCryst Pharmaceuticals Inc, Subsidiaries
  • BioCryst Pharmaceuticals Inc, Key Competitors
  • BioCryst Pharmaceuticals Inc, Ratios based on current share price
  • BioCryst Pharmaceuticals Inc, Annual Ratios
  • BioCryst Pharmaceuticals Inc, Interim Ratios
  • BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • BioCryst Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • BioCryst Pharmaceuticals Inc, Performance Chart (2018 - 2022)
  • BioCryst Pharmaceuticals Inc, Ratio Charts
  • BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Velico Medical Inc
  • Ionis Pharmaceuticals Inc
  • GSK plc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Daiichi Sankyo Co Ltd
  • Arbutus Biopharma Corp
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Arbutus Biopharma Corp
  • Ionis Pharmaceuticals Inc
  • Velico Medical Inc
  • GSK plc
  • Daiichi Sankyo Co Ltd